A Phase 1 Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas
Status:
Completed
Trial end date:
2020-12-03
Target enrollment:
Participant gender:
Summary
This will be a Phase 1, open-label study of milademetan to assess its safety and
tolerability, identify a maximum tolerated dose (MTD)/tentative recommended phase 2 dose
(RP2D), and assess its pharmacokinetic (PK)/ pharmacodynamic (PDy) properties in participants
with advanced solid tumors or lymphomas.
Approximately 5 US sites are planned for Part 1 (Dose Escalation) and Part 2 (Dose
Expansion). The same sites are planned to participate for both parts.